Relapse of hepatitis C virus after 14 months of sustained virological response following pegylated-interferon alpha plus ribavirin therapy in a human immunodeficiency virus type 1 infected patient

Journal of Clinical Virology

Volumn 58, Issue 1, 2013, Pages 309-314

  Colson, Philippe ^a,b   Bregigeon, Sylvie ^c   Tourres, Christian ^a,b   Solas, Caroline ^c   Poizot Martin, Isabelle ^c   Tamalet, Catherine ^a,b  

^a INSERM   (France)

^b TIMONE HOSPITAL   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

HCV recurrence; Hepatitis C virus; HIV HCV coinfection; Pegylated interferon alpha plus ribavirin therapy

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ASPARTATE AMINOTRANSFERASE; HEMOGLOBIN; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NONSTRUCTURAL PROTEIN 5B; PEGINTERFERON ALPHA; RIBAVIRIN; ZIDOVUDINE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CD4 LYMPHOCYTE COUNT; DRUG MONITORING; ELASTOGRAPHY; FOLLOW UP; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ABUSE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; MIXED INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; PHYLOGENY; PRIORITY JOURNAL; RELAPSE; ULTRASOUND; VIRUS LOAD; VIRUS STRAIN;

EID: 84881557959     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2013.05.009     Document Type: Article

References (21)

1. Chung R.T., Andersen J., Volberding P., Robbins G.K., Liu T., Sherman K.E., et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004, 351:451-559.
2. Von Wagner M., Huber M., Berg T., Hinrischen H., Rasenack J., Bergk A., et al. Peginterferon alfa-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005, 129:522-527.
3. Huang C.F., Dai C.Y., Huang J.F., Chuang W.L., Yu M.L. A crossing in therapy for hepatitis C virus genotype 2 or 3: increasing ribavirin dose with shortened duration or reducing ribavirin dose with standard duration. Hepatology 2009, 49:1395-1396.
4. Pawlotsky J.M. Hepatitis C virus: from discovery to eradication in 40 years?. Clin Microbiol Infect 2011, 17:105-106.
5. Taylor L.E., Swan T., Mayer K.H. HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis 2012, Suppl 1:S33-S42.
6. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011, 55:245-264.
7. Pawlotsky J.M., Chevaliez S., McHutchinson J.G. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007, 132:1979-1998.
8. Lee W.M., Polson J.E., Carney D.S., Sahin B., Gale M. Reemergence of hepatitis C virus after 8.5 years in a patient with hypogammaglobulinemia: evidence for an occult viral reservoir. J Infect Dis 2005, 192:1088-1092.
9. Thomopoulos K., Giannakoulas N.C., Tsamandas A.C., Mimidis K., Fragopanagou E., Pallasopoulou M., et al. recurrence of HCV infection in a sustained responder after chemotherapy for non-Hodgkin's lymphoma: successful retreatment. Am J Med Sci 2008, 336:73-76.
10. Fujii H., Itoh Y., Ohnishi N., Sakamoto M., Ohkawara T., Sawa Y., et al. relapse of hepatitis C in a pegylated-interferon-a-2b plus ribavirin treated sustained virological responder. Hepatol Res 2010, 40:654-660.
11. Tamalet C., Colson P., Tissot-Dupont H., Henry M., Tourres C., Tivoli N., et al. Genomic and phylogenetic analysis of hepatitis C virus isolates: a survey of 535 strains circulating in southern France. J Med Virol 2003, 71:391-398.
12. Henry M., Tourres C., Colson P., Ravaux I., Poizot-Martin I., Tamalet C. Coexistence of the K65R/L74V and/or K65R/T215Y mutations on the same HIV-1 genome. J Clin Virol 2006, 37:227-230.
13. Colson P., Brouk N., Limbo F., Castellani P., Tamalet C., Gerolami R. Natural presence of substityution R155K within hepatitis C virus NS3 protease from a treatment-naïve chronically infected patient. Hepatology 2008, 47:766-767.
14. McHutchinson J.G., Poynard T., Esteban-Mur R., Davis G.L., Goodman Z.D., Harvey J., et al. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology 2002, 35:688-693.
15. Pham T.N., MacParland S.A., Mulrooney P.M., Cooksley H., Naoumov N.V., Michalak T.I. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 2004, 78:5867-5874.
16. Radkowski M., Gallegos-Orozco J.F., Jablonska J., Colby T.V., Walewska-Zielecka B., Kubicka J., et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005, 41:106-114.
17. Castillo I., Rodriguez-Inigo E., Lopez-Alcorocho J.M., Pardo M., Bartolomé J., Carreno V. Hepatitis C virus replicated in the liver of patients who have a sustained response to antiviral treatment. Clin Infect Dis 2006, 43:1277-1283.
18. Laskus T., Radkowski M., Piasek A., Nowicki M., Horban A., Cianciara J., et al. Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis 2000, 181:442-448.
19. Laskus T., Operskalski E.A., Radkowski M., Wilkinson J., Mack W.J., deGiacomo M., et al. Negative-strand hepatitis C Virus (HCV) RNA in peripheral blood mononuclear cells from anti-HCV-positive/HIV-infected women. J Infect Dis 2007, 195:124-133.
20. Simmonds P., Bukh J., Combet C., Deléage G., Enomoto N., Feinstone S., et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005, 42:962-973.
21. Grebely J., Knight E., Ngai T., Genoway K.A., Raffa J.D., Storms M., et al. Reinfection with hepatitis C virus following sustained virological response in injection drug users. Hepatology 2010, 25:1281-1284.